OneOncology and Genentech today announced a partnership that will facilitate increased personalized cancer care at community oncology centers nationwide. The multi-year collaboration will include clinical trials, scientific research, and real-world data studies with a goal of enhancing clinical assessment of comprehensive genomic profiling (CGP), increasing access to clinical trials, and broadening the range of therapeutic options for patients at community oncology practices. Assessing tumors for potential genomic alterations through CGP can be a game-changer for cancer patients, allowing physicians to determine which treatments will be effective for their specific disease. But in community oncology settings, its use is still limited. The OneOncology-Genentech collaboration seeks to both contribute to research in that area and make the most cutting-edge technology more available to patients at community practices.